|
International Consultation on Sexual Medicine Report
To review the current data on pharmacotherapy for erectile dysfunction based on efficacy, psychosocial outcomes, and safety outcomes. A review of the literature was undertaken by the committee members. All related articles were critically analyzed and discussed.
Pharmacotherapy for Erectile Dysfunction: Recommendations ...
To review the current data on pharmacotherapy for erectile dysfunction based on efficacy, psychosocial outcomes, and safety outcomes. A review of the literature was undertaken by the committee members. All related articles were critically analyzed and discussed.
(PDF) Pharmacotherapy for Erectile Dysfunction ... - ResearchGate
Aim: To review the current data on pharmacotherapy for erectile dysfunction based on efficacy, psychosocial outcomes, and safety outcomes. Methods: A review of the literature was undertaken...
Pharmacotherapy for Erectile Dysfunction: Recommendations ...
To review the current data on pharmacotherapy for erectile dysfunction based on efficacy, psychosocial outcomes, and safety outcomes. A review of the literature was undertaken by the committee members. All related articles were critically analyzed and discussed.
Pharmacotherapy for Erectile Dysfunction: Recommendations ...
To review the current data on pharmacotherapy for erectile dysfunction based on efficacy, psychosocial outcomes, and safety outcomes. A review of the literature was undertaken by the committee members. All related articles were critically analyzed and discussed.
Pharmacotherapy for Erectile Dysfunction: Recommendations ...
The aim of this article is to present a summary of the report generated from the Fourth ICSM (2015) and the committee on Pharmacotherapy for ED, Testosterone De ficiency and Sexual...
Pharmacotherapy for erectile dysfunction. - Europe PMC
Phosphodiesterase type 5 (PDE5) inhibitors are first-line therapy for most men with erectile dysfunction who do not have a specific contraindication to their use. There is no evidence of significant differences in efficacy, safety, and tolerability between the PDE5 inhibitors and apomorphine.
|